Clinical trials: Acute Lymphocytic Leukaemia
Acute Leukemia, Acute Myeloid Leukemia (AML)
Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding
This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukaemia
- Trial name
- BAIT (NCT06947044)
- Testing
- RBC transfusion strategy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Donald Arnold
Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological…
- Conditions
- Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
- Trial name
- NCT05086315
- Testing
- SAR443579
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 101 people
- Sponsor
- Sanofi
Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell…
- Conditions
- Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT06037018
- Testing
- CC312
- Where
- China
- Volunteers
- 44 people
- Sponsor
- CytoCares Inc
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
This trial investigates stem cell transplants from partially mismatched donors in patients with blood and bone marrow cancers. The trial will test two kinds of transplants - a full intensity transplant using a high dose of…
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Myeloid Leukaemia, Acute Lymphoblastic Leukaemia
- Trial name
- UK-Haplo (NCT01597219)
- Testing
- Reduced intensity haplodentical stem cell transplant, Myeloablative haploidentical stem cell transplant
- Where
- 12 sites in United Kingdom
- Volunteers
- 77 people
- Sponsor
- University College, London
Acute Lymphocytic Leukaemia
SAR3419 in Acute Lymphoblastic Leukemia
Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: Response duration Progression Free Survival Minimal residual disease Safety Pharmacokinetics
- Trial name
- MYRALL (NCT01440179)
- Testing
- SAR3419
- Where
- 11 sites in United States, France
- Volunteers
- 100 people
- Sponsor
- Sanofi
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory
- Trial name
- NCT04603872
- Testing
- CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University